Page 31 - Drug Class Review

Final Report Update 1 Drug Effectiveness Review Project

Author, Year Mean N Duration Disease Results Quality
Age (weeks) Severity Rating
(years)
Tairot et al., 2000 52, 77 978 22 Mild - Symptoms: significantly slower decline in Fair
64, 65
moderate cognitive and global assessment
scores for GAL 16-24mg/d
Behavior / function: slower decline of
measures of daily function and
behavior for GAL 16-24mg/d; 24mg/d
had significant reduction in caregiver
burden compared to placebo
Wilcock et al., 72 653 26 Mild - Symptoms: significantly slower decline in Good
53
2000 moderate cognitive and global assessment
scores for GAL 24-32mg/d
Behavior / function: GAL 32mg/d (but not
24mg/d) patients had significantly less
disability
Wilkinson et al., 74 285 12 Mild - Symptoms: significantly more Fair
54
2001 moderate improvement in cognitive scores for
GAL 24mg/d; no significant differences
in global improvement
Behavior / function: No differences in
functioning
Rivastigmine vs. Placebo
Birks et al., 2004 NR 3,45 > 2 NR Symptoms: Pooled: RIV (all doses) Good
37
(SR) 0 significantly better than placebo on
CIBIC-plus; only RIV 6-12mg/d
significantly better on ADAS-cog,
MMSE, and GDS
Behavior / function: Pooled: RIV 6-
12mg/d (but not RIV 1-4mg/d) better
than placebo on measures of
functioning
Schneider et al., 73 2,12 26 Mild - Symptoms: significantly more Fair
1998 (SR) 35,74,75 6 moderate improvement in behavior and global
function for RIV (all doses)
Behavior / function: RIV (all doses)
significantly better than placebo on
measures of function
Agid et al., 1998 56 70 402 13 NR Symptoms: RIV 6mg/day (but not Fair
4mg/day) significantly better than
placebo for clinical impression
outcomes
Behavior / function: RIV 6mg/d (but not
4mg/d) better than placebo on
measures of behavior
Corey-Bloom et al., 75 699 26 Mild - Symptoms: RIV (all doses) significantly Fair
55
1998 moderate better than placebo on measures of
global function
Behavior / function: RIV 6-12mg/d (but
not RIV 1-4mg/d) better than placebo
on measures of functioning
Rosler et al., 1999 57 NR 725 26 Mild - Symptoms: RIV 6-12mg/d significantly Fair
moderate better on measures of global function;
no differences between RIV 1-4mg/d
and placebo
Behavior / function: RIV 6-12mg/d (but
not RIV 1-4mg/d) better than placebo
for daily function

Alzheimer's Drugs Page 31 of 205